Diabetic Neuropathic Pain Market Insights, Trends & Analysis 2015

1
Diabetic Neuropathic Pain Pipeline Review, H2 2015
No. Pages 102
Published on October - 2015
2
.
Report Overview
About Diabetic Neuropathic Pain Pipeline Review,
H2 2015 Research Beam added report on Diabetic
Neuropathic Pain Pipeline Review, H2 2015.
Summary Global Markets Directs, Diabetic
Neuropathic Pain Pipeline Review, H2 2015,
provides an overview of the Diabetic Neuropathic
Pain s therapeutic pipeline. This report provides
comprehensive information on the therapeutic
development for Diabetic Neuropathic Pain,
complete with comparative analysis at various
stages, therapeutics assessment by drug target,
mechanism of action (MoA), route of
administration (RoA) and molecule type, along
with latest updates, and featured news and press
releases. It also reviews key players involved in
the therapeutic development for Diabetic
Neuropathic Pain and special features on
late-stage and discontinued projects. Get Full
Details On http//www.researchbeam.com/diabetic-
neuropathic-pain-pipeline-review-h2-2015-market

3
.
Report Overview
Global Markets Directs report features
investigational drugs from across globe covering
over 20 therapy areas and nearly 3,000
indications. The report is built using data and
information sourced from Global Markets Directs
proprietary databases, Company/University
websites, SEC filings, investor presentations and
featured press releases from company/university
sites and industry-specific third party sources,
put together by Global Markets Directs team. Drug
profiles/records featured in the report undergoes
periodic updation following a stringent set of
processes that ensures that all the profiles are
updated with the latest set of information.
Additionally, processes including live news
deals tracking, browser based alert-box and
clinical trials registries tracking ensure that
the most recent developments are captured on a
real time basis. The report enhances decision
making capabilities and help to create effective
counter strategies to gain competitive advantage.
It strengthens RD pipelines by identifying new
targets and MOAs to produce first-in-class and
best-in-class products. Note Certain sections
in the report may be removed or altered based on
the availability and relevance of data for the
indicated disease.  
4
.
Report Overview
Scope The report provides a snapshot of the
global therapeutic landscape of Diabetic
Neuropathic Pain The report reviews key pipeline
products under drug profile section which
includes, product description, MoA and RD brief,
licensing and collaboration details other
developmental activities The report reviews key
players involved in the therapeutics development
for Diabetic Neuropathic Pain and enlists all
their major and minor projects The report
summarizes all the dormant and discontinued
pipeline projects A review of the Diabetic
Neuropathic Pain products under development by
companies and universities/research institutes
based on information derived from company and
industry-specific sources Pipeline products
coverage based on various stages of development
ranging from pre-registration till discovery and
undisclosed stages. A detailed assessment of
monotherapy and combination therapy pipeline
projects Coverage of the Diabetic Neuropathic
Pain pipeline on the basis of target, MoA, route
of administration and molecule type  
5
Report Overview
Reasons to buy  Provides strategically
significant competitor information, analysis, and
insights to formulate effective RD development
strategies Identify emerging players with
potentially strong product portfolio and create
effective counter-strategies to gain competitive
advantage Develop strategic initiatives by
understanding the focus areas of leading
companies Identify and understand important and
diverse types of therapeutics under development
for Diabetic Neuropathic Pain Plan mergers and
acquisitions effectively by identifying key
players of the most promising pipeline Devise
corrective measures for pipeline projects by
understanding Diabetic Neuropathic Pain pipeline
depth and focus of Indication therapeutics Develop
and design in-licensing and out-licensing
strategies by identifying prospective partners
with the most attractive projects to enhance and
expand business potential and Scope Modify the
therapeutic portfolio by identifying discontinued
projects and understanding the factors that drove
them from pipeline  
6
Table Of Contents
List of Tables 6List of Figures 7Introduction
8Global Markets Direct Report Coverage
8Diabetic Neuropathic Pain Overview
9Therapeutics Development 10Pipeline Products
for Diabetic Neuropathic Pain - Overview
10Pipeline Products for Diabetic Neuropathic
Pain - Comparative Analysis 11Diabetic
Neuropathic Pain - Therapeutics under Development
by Companies 12Diabetic Neuropathic Pain -
Therapeutics under Investigation by
Universities/Institutes 15Diabetic Neuropathic
Pain - Pipeline Products Glance 16Late Stage
Products 16Clinical Stage Products 17Early
Stage Products 18
7
Table Of Contents
Diabetic Neuropathic Pain - Products under
Development by Companies 19Diabetic Neuropathic
Pain - Products under Investigation by
Universities/Institutes 20Diabetic Neuropathic
Pain - Companies Involved in Therapeutics
Development 21Astellas Pharma Inc.
21AstraZeneca Plc 22BioDelivery Sciences
International, Inc. 23Boehringer Ingelheim GmbH
24Daiichi Sankyo Company, Limited 25Dong-A
Socio Group 26Eli Lilly and Company 27Glenmark
Pharmaceuticals Ltd. 28Hydra Biosciences, Inc.
29Immune Pharmaceuticals Inc. 30Laboratorios
Del Dr. Esteve S.A. 31
8
Table Of Contents
Lohocla Research Corporation 32 Mertiva AB
33Novaremed 34Pharmaleads 35RAPID
Pharmaceuticals AG 36Relmada Therapeutics, Inc.
37Sphaera Pharma Pvt. Ltd. 38Theravasc, Inc.
39Diabetic Neuropathic Pain - Therapeutics
Assessment 40 Enquiry about this report _at_
http//www.researchbeam.com/diabetic-neuropathic-p
ain-pipeline-review-h2-2015-market/enquire-about-r
eport
9
FOR MORE DETAILS
Visit us at
http//www.researchbeam.com/diabetic-neuropathic-p
ain-pipeline-review-h2-2015-market
Stay With Us
5933 NE Win Sivers Drive,205, Portland, OR
97220United States
TELEPHONE [phone] E-MAIL
sales_at_researchbeam.com